EUCTR2017-003040-20-RO进行中（未招募）1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 790
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age >=18 years
- •Histologically-confirmed metastatic or advanced unresectable CUP
- •At least one lesion that is measurable according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- •Availability of a tumor Formalin-fixed paraffin-embedded(FFPE) block <=3 months old at Screening that is sufficient for generation of a Foundation One® comprehensive genomic profile at a central reference pathology laboratory
- •Availability of test reports confirming local CUP diagnosis If test reports confirming local CUP diagnosis are not available, an FFPE block must be submitted that is sufficient to allow for central confirmation of CUP diagnosis
- •Each patient must provide a blood sample for Foundation ACT® genomic profiling, which will be used to assign molecularly-guided therapy ONLY in those patients for whom a Foundation One® report could not be generated
- •No prior systemic therapy for the treatment of CUP
- •ECOG performance status of 0 or 1
- •Life expectancy >=12 weeks
- •Eligible for platinum-based doublet chemotherapy
- •Adequate hematologic and end-organ function
- •Use of appropriate contraceptive methods
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 600
排除标准
- •Squamous cell CUP
- •Patients with any of the specific non-CUP neoplasms identified in the ESMO CUP guidelines, including:
- •Non-epithelial cancer and extra gonadal germ-cell tumor
- •Patients belonging to any of the following subsets of CUP with favorable prognoses: Poorly differentiated carcinoma with midline distribution, Women with papillary adenocarcinoma of the peritoneal cavity and adenocarcinoma involving only the axillary lymph nodes, Squamous cell carcinoma of the cervical lymph nodes, poorly differentiated neuroendocrine tumors, Men with blastic bone metastases and elevated prostate-specific antigen, Patients with a single, small, potentially resectable tumor, Colon cancer-type CUP
- •Known presence of brain or spinal cord metastasis, as determined by CT or magnetic resonance imaging evaluation during screening
- •History or known presence of leptomeningeal disease
- •Uncontrolled or symptomatic hypercalcemia
- •Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis and human immunodeficiency virus infection
- •Positive for hepatitis C virus antibody and hepatitis B surface antigen, and active tuberculosis at screening
- •Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
- •History of malignancy other than CUP within 5 years prior to screening
- •Prior allogeneic stem cell or solid organ transplantation
- •Known allergy or hypersensitivity to any component of the platinum-doublet chemotherapy
- •Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 24 months after the last dose of treatment
研究者
相似试验
进行中（未招募）
1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapyCancer of Unknown Primary SiteMedDRA version: 20.0Level: LLTClassification code 10032248Term: Other malignant neoplasm of unspecified siteSystem Organ Class: 100000004864EUCTR2017-003040-20-IEF. Hoffmann-La Roche Ltd790
进行中（未招募）
1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapyCancer of Unknown Primary SiteMedDRA version: 20.0Level: LLTClassification code 10032248Term: Other malignant neoplasm of unspecified siteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003040-20-BGF. Hoffmann-La Roche Ltd528
进行中（未招募）
1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapyCancer of Unknown Primary SiteMedDRA version: 20.0Level: LLTClassification code 10032248Term: Other malignant neoplasm of unspecified siteSystem Organ Class: 100000004864EUCTR2017-003040-20-ITF. HOFFMANN - LA ROCHE LTD.790
进行中（未招募）
1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapyEUCTR2017-003040-20-FIF. Hoffmann-La Roche Ltd790
进行中（未招募）
1 期
A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapyCancer of Unknown Primary SiteMedDRA version: 20.0Level: LLTClassification code 10032248Term: Other malignant neoplasm of unspecified siteSystem Organ Class: 100000004864EUCTR2017-003040-20-ESRoche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffman-La Roche LTD790